Durveqtix%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252520gene%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252520therapy

# Durveqtix gene therapy ## Overview Durveqtix (dihydrofilmira) is a gene therapy indicated for the treatment of hemophilia A. It is a one-time infusion designed to provide a functional copy of the Factor VIII (FVIII) gene. ## Primary Indications Durveqtix is indicated for the prophylactic treatment to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. ## Adult Dosing The recommended dose of Durveqtix is a one-time intravenous infusion of 6 x 10^13 vector genomes per kilogram (vg/kg). ## Pediatric Dosing The recommended dose of Durveqtix is a one-time intravenous infusion of 6 x 10^13 vector genomes per kilogram (vg/kg). ## Dose Adjustments No dose adjustments are typically required. However, the decision to administer Durveqtix and potential management of adverse events should be guided by a healthcare professional experienced in treating hemophilia. ## Contraindications Durveqtix is contraindicated in patients with known hypersensitivity to the active substance, any of the excipients, or to AAV serotype rh10. ## Adverse Effects The most common adverse reactions observed in clinical trials include elevated liver enzymes (ALT, AST), headache, infusion-related reactions, and increased levels of uric acid. Immune responses to the AAV capsid are expected and may impact efficacy or lead to adverse events. ## Key Drug Interactions * **Corticosteroids:** Concomitant use of corticosteroids may be required to manage immune responses. However, the impact of corticosteroids on Durveqtix efficacy is not fully characterized. * **Immunosuppressants:** The use of immunosuppressants should be carefully considered, as they may alter the immune response to Durveqtix. ## Monitoring * **Liver Function Tests:** Monitor ALT, AST, and bilirubin levels periodically. * **FVIII Activity Levels:** Monitor FVIII activity to assess response to treatment. * **Antibody Titers:** Monitor for the development of neutralizing antibodies to AAV. ## Clinical Pearls * Durveqtix is a one-time infusion. * Patients should be monitored for potential immune reactions, particularly liver enzyme elevations. * Management of bleeding episodes while on Durveqtix should be guided by FVIII activity levels and clinical assessment. *** **Disclaimer:** This information is intended for healthcare professionals. Please consult the official prescribing information and current clinical guidelines for complete and up-to-date details regarding Durveqtix therapy.